Quality of life in Brazilian patients with treated or untreated chronic hepatitis C

Perlin, Cássio Marques; Ferreira, Vinicíus Lins; Borba, Helena Hiemisch Lobo; Wiens, Astrid; Ivantes, Claudia Alexandra Pontes; Lenzi, Luana; Pontarolo, Roberto

doi:10.1590/s1678-9946201759081

Cited by 9 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study conducted in Brazil compared the quality of life of chronic hepatitis C patients receiving antiviral interferon-based therapies, including interferon and RBV, in some cases combined with first-generation DAAs boceprevir and telaprevir 20 . Besides the clinical conditions of those patients, HRQoL was affected by treatment complications, which were associated with a significant number of side effects, low efficacy, treatment discontinuations and the requirement of frequent injections 21 – 23 .…”

Section: Discussionmentioning

confidence: 99%

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Siqueira

Ferreira

Borba

et al. 2018

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

Due to the severity of chronic hepatitis C, there are multiple factors that can negatively affect the quality of life of infected patients. The aim of this study was to evaluate changes in the health-related quality of life (HRQoL) in patients under second-generation direct-acting antiviral (DAA) (interferon-free) therapies and to assess treatment effectiveness. This was an observational study conducted in Curitiba (Brazil) using two instruments (a generic and a specific) for measuring the quality of life in patients with chronic hepatitis C, the Short Form-36 (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) for liver disease evaluation. The study included patients receiving any interferon-free therapy for hepatitis C treatment during 2016 and 2017. Data were collected before, during, and after treatment regarding the two questionnaires, effectiveness and safety. Fifty-six patients fulfilled all eligibility criteria and were included for analysis. Sustained virological response was obtained in 88% of the patients. They were mainly genotype 1, cirrhotic and treated with sofosbuvir combined with daclatasvir or sofosbuvir with simeprevir. Improvement in the quality of life was observed for several domains in both questionnaires (p < 0.05) in the comparison before and after treatment. Patients receiving sofosbuvir with daclatasvir had significantly lower scores compared to the group receiving sofosbuvir with simeprevir. Second-generation DAA therapies were effective and have considerably increased the HRQoL of patients with chronic hepatitis C virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Siqueira

Ferreira

Borba

et al. 2018

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

show abstract

“…The HCV genome encodes three structural (Core, E1 and E2) and seven non-structural (NS) proteins (NS1 or P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)[1]. As a kind of hepatic tropism virus, HCV mainly replicates in the hepatocyte cytoplasm and frequently causes acute or chronic hepatitis C (CHC), which has an estimated prevalence of 71 million people and is responsible for approximately 399000 deaths annually[1,2]. CHC patients generally experience liver diseases ranging from liver fibrosis and cirrhosis to hepatocellular carcinoma (HCC) and suffer from metabolic disorders such as lipid abnormalities, steatosis, insulin resistance, and iron load dysregulation[3].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy

Li¹,

Huang²,

Jiang³

et al. 2018

WJG

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection commonly causes progressive liver diseases that deteriorate from chronic inflammation to fibrosis, cirrhosis and even to hepatocellular carcinoma. A long-term, persistent and uncontrolled inflammatory response is a hallmark of these diseases and further leads to hepatic injury and more severe disease progression. The levels of inflammatory cytokines and chemokines change with the states of infection and treatment, and therefore, they may serve as candidate biomarkers for disease progression and therapeutic effects. The mechanisms of HCV-induced inflammation involve classic pathogen pattern recognition, inflammasome activation, intrahepatic inflammatory cascade response, and oxidative and endoplasmic reticulum stress. Direct-acting antivirals (DAAs) are the first-choice therapy for effectively eliminating HCV, but DAAs alone are not sufficient to block the uncontrolled inflammation and severe liver injury in HCV-infected individuals. Some patients who achieve a sustained virologic response after DAA therapy are still at a long-term risk for progression to liver cirrhosis and hepatocellular carcinoma. Therefore, coupling with anti-inflammatory/hepatoprotective agents with anti-HCV effects is a promising therapeutic regimen for these patients during or after treatment with DAAs. In this review, we discuss the relationship between inflammatory mediators and HCV infection, summarize the mechanisms of HCV-induced inflammation, and describe the potential roles of anti-inflammatory/hepatoprotective drugs with anti-HCV activity in the treatment of advanced HCV infection.

show abstract

“…During treatment, quality of life was impaired by IFN-based therapies due to a significant number of side effects and also due to injections of IFN. On the other hand, quality of life did not change in patients who received DAAs [25].…”

Section: Discussionmentioning

confidence: 85%

Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term

Atamla

Khoury

Dabbah

et al. 2021

ceh

View full text Add to dashboard Cite

Introduction: Direct antiviral agents (DAAs) are new drugs for the treatment of chronic hepatitis C virus (HCV) infection. These drugs are very effective and well tolerated. HCV can cause liver disease as well as extrahepatic manifestations, including a profound negative impact on health-related quality of life (HRQL). Aim of the study: To evaluate HRQL in the long term (> 6 months after finishing treatment) after successful treatment with DAAs. To the best of our knowledge, this is the first study that evaluates quality of life in the long term after DAA treatment. Material and methods: This is an observational study which included 100 patients treated with DAAs for chronic HCV infection between January 2015 and August 2018. Patients were assigned randomly. The average time after finishing treatment was 29.96 months. The Liver Disease Symptom Index (LDSI) 2.0 Questionnaire was used to evaluate quality of life before and after treatment. Results: Seven of 9 parameters of the LDSI 2.0 Questionnaire showed significant improvement in the long term after successful treatment with DAAs. Two parameters (arthralgia and jaundice) did not improve significantly. Quality of life improved in both males and females similarly. Improvement did not correlate with the severity of liver fibrosis. Conclusions: Treatment with DAAs improves HRQL significantly in the long term.

show abstract

Quality of life in Brazilian patients with treated or untreated chronic hepatitis C

Cited by 9 publications

References 37 publications

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies

Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy

Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term

Contact Info

Product

Resources

About